Enfermedades renales tubulointersticiales. Formas crónicas

  1. de la Fuente, G. de Arriba
  2. Sevillano, B. Hernández
  3. del Valle, K.M. Pérez
  4. Gili, B. Quiroga
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2019

Título del ejemplar: Enfermedades nefrourinarias (V)Enfermedades renales tubulointersticiales.Nefropatías hereditarias y congénitas

Serie: 12

Número: 83

Páginas: 4872-4877

Tipo: Artículo

DOI: 10.1016/J.MED.2019.06.021 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

In chronic tubulointerstitial kidney diseases (CTKD), primary damage is on, commonly, tubules and interstitium causing a range of clinical features. However, several conditions causing glomerular and vascular damage can provoke secondary chronic tubulointerstitial kidney, often associated with poor long-term prognosis. The etiology of CTKDs is very diverse and includes urological, metabolic, pharmacologic causes, systemic diseases and physicochemical factors, among others. Since kidney biopsy is unspecific, clinical suspicion and imaging tests are basis of its diagnosis. Since there are hardly any treatments that can inhibit the mechanisms of interstitial fibrosis, therapeutic options are damage prophylaxis, treatment of underlying disease, and control of the damage risk factors.

Referencias bibliográficas

  • Bennett WM. Lead nephropathy. Kidney Int. 1985;28(2):212-20.
  • Clark MR, Trotter K, Chang A. The pathogenesis and therapeutic implications of tubulointerstitial inflammation in human lupus nephritis. Semin Nephrol [Internet]. 2015;35(5):455-64.
  • Cooper RD, Tonelli M. Renal disease associated with antiretroviral the-rapy in the treatment of HIV. Nephron Clin Pract. 2011;118(3):c262-8.
  • David D, Princiero Berlingerio S, Elmonem MA, Oliveira Arcolino F, Soliman N, van den Heuvel B. Molecular basis of cystinosis: geographic distribution, functional consequences of mutations in the ctns gene, and potential for repair. Nephron. 2019;141(2):133-46.
  • Dindo M, Conter C, Oppici E, Ceccarelli V, Marinucci L, Cellini B. Molecular basis of primary hyperoxaluria: clues to innovative treatments. Urolithiasis. 2019;47(1):67-78.
  • Dong W, Qiu B, Liu H, He L. Undiagnosed renal sarcoidosis in a patient with chronic interstitial nephritis. Clin Rheumatol [Internet]. 2017;36(11): 2619-22.
  • Francois H, Mariette X. Renal involvement in primary Sjogren syndrome. Nat Rev Nephrol. 2016;12(2):82-93.
  • Galan I, Goicoechea M, Quiroga B, Macias N, Santos A, Garcia de Vinuesa MS. Hyperuricemia is associated with progression of chronic kidney disease in patients with reduced functioning kidney mass. Nefro-logia. 2018;38(1):73-8.
  • Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A. Allopurinol and progression of CKD and cardiovascular events: long term follow up of a randomized clinical trial. Am J Kidney Dis. 2015;65(4):543-9.
  • Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol. 2013;37(6): 602-12.
  • Jadot I, Declèves A-E, Nortier J, Caron N. An integrated view of aristolochic acid nephropathy: update of the literature. Int J Mol Sci [Internet]. 2017;18(2):297.
  • Kawano M, Yamada K. IgG4-related kidney disease and IgG4-related retroperitoneal fibrosis. Semin Liver Dis [Internet]. 2016;36(03):283-90.
  • Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol [Internet]. 2018;31(1):15-25.
  • McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet (London, England). 2012;379(9817):721-8.
  • Meola M, Samoni S, Petrucci I. Clinical scenarios in chronic kidney disease: chronic tubulointerstitial diseases. Contrib Nephrol. 2016;188:108-19.
  • Nazzal L, Puri S, Goldfarb DS. Enteric hyperoxaluria: an important cause of end stage kidney disease. Nephrol Dial Transplant. 2016;31(3): 375-82
  • Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19(12):2407-13.
  • Oliva-Damaso N, Oliva-Damaso E, Payan J. Acute and Chronic Tubu-lointerstitial Nephritis of Rheumatic Causes. Rheum Dis Clin North Am [Internet]. 2018 Nov;44(4):619-33.
  • Perazella MA. Clinical approach to diagnosing acute and chronic tubulointerstitial disease. Adv Chronic Kidney Dis [Internet]. 2017;24(2):57-63.
  • Quattrocchio G, Roccatello D. IgG4-related nephropathy. J Nephrol [Internet]. 2016;29(4):487-93.
  • Sandler DP, Smith JC, Weinberg CR, Buckalew VM, Dennis VW, Blythe WB. Analgesic use and chronic renal disease. N Engl J Med [Internet]. 1989;320(19):1238-43.
  • Schnaper HW. The tubulointerstitial pathophysiology of progressive kidney disease. Adv Chronic Kidney Dis [Internet]. 2017;24(2):107-16.
  • Schwarz A, Krause PH, Kunzendorf U, Keller F, Distler A. The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol. 2000;54(3):179-90
  • Stiborova M, Arlt VM, Schmeiser HH. Balkan endemic nephropathy: an update on its aetiology. Arch Toxicol. 2016;90(11):2595-615.
  • Zhang P, Cornell LD. IgG4-related tubulointerstitial nephritis. Adv Chronic Kidney Dis [Internet]. 2017;24(2):94-100.
Fuente de los datos: Dialnet